News & Updates
Filter by Specialty:

Tenecteplase at 4.5–24 hours without thrombectomy feasible for ischaemic stroke
The use of tenecteplase in the extended time window of 4.5–24 hours improves functional outcomes in patients with ischaemic stroke when endovascular thrombectomy (EVT) is not immediately available, findings from the phase III TRACE-III* trial suggest.
Tenecteplase at 4.5–24 hours without thrombectomy feasible for ischaemic stroke
11 Sep 2024
High leptin levels linked to lower risk of Alzheimer’s disease
A study has recently observed the possible protective effect of leptin against the development of Alzheimer’s disease (AD) by improving insulin sensitivity.
High leptin levels linked to lower risk of Alzheimer’s disease
09 Sep 2024
SGLT-2 inhibitors may prevent dementia in adults with T2D
Initiation of sodium-glucose cotransporter-2 (SGLT-2) inhibitors results in a 35-percent reduced risk of dementia compared with dipeptidyl peptidase-4 (DPP-4) inhibitors in individuals with type 2 diabetes (T2D) aged 40–69 years, according to a study. In addition, greater benefits are seen with longer treatment duration.
SGLT-2 inhibitors may prevent dementia in adults with T2D
07 Sep 2024
VTE incidence similar among common SGAs
The incidence of venous thromboembolism (VTE) does not appear to significantly differ among patients treated with second-generation antipsychotics (SGAs) such as risperidone, olanzapine, or aripiprazole, results of a study have shown.
VTE incidence similar among common SGAs
05 Sep 2024
Tau-PET: Best predictor for dementia progression in MCI patients
Tau-PET outperforms amyloid-β (Aß) PET and MRI as the best neuroimaging marker for predicting progression to dementia in patients with mild cognitive impairment (MCI), a cohort study has shown.